MidFirst Bank purchased a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 4,375 shares of the company’s stock, valued at approximately $2,960,000.
A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Elyxium Wealth LLC acquired a new stake in IDEXX Laboratories in the fourth quarter valued at approximately $3,666,459,000. J. Stern & Co. LLP lifted its position in shares of IDEXX Laboratories by 23,694.7% during the fourth quarter. J. Stern & Co. LLP now owns 2,653,351 shares of the company’s stock worth $1,795,072,000 after purchasing an additional 2,642,200 shares in the last quarter. Northwestern Mutual Wealth Management Co. lifted its position in shares of IDEXX Laboratories by 63,503.9% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 1,444,445 shares of the company’s stock worth $977,210,000 after purchasing an additional 1,442,174 shares in the last quarter. Wellington Management Group LLP boosted its stake in shares of IDEXX Laboratories by 318.1% in the fourth quarter. Wellington Management Group LLP now owns 779,214 shares of the company’s stock valued at $527,162,000 after purchasing an additional 592,834 shares during the period. Finally, Norges Bank purchased a new position in shares of IDEXX Laboratories in the fourth quarter valued at $332,265,000. Hedge funds and other institutional investors own 87.84% of the company’s stock.
Analyst Upgrades and Downgrades
A number of equities research analysts recently weighed in on IDXX shares. UBS Group lowered their price target on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a report on Tuesday, April 28th. Stifel Nicolaus cut their price objective on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a report on Tuesday, March 31st. Weiss Ratings cut shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 11th. Citigroup started coverage on IDEXX Laboratories in a research note on Wednesday, April 15th. They set a “neutral” rating and a $650.00 target price for the company. Finally, Wall Street Zen raised IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Saturday, June 13th. Seven research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $751.00.
IDEXX Laboratories Stock Up 2.9%
Shares of IDEXX Laboratories stock opened at $562.09 on Friday. The company has a quick ratio of 0.82, a current ratio of 1.12 and a debt-to-equity ratio of 0.19. The firm has a market cap of $44.34 billion, a P/E ratio of 41.39, a P/E/G ratio of 2.99 and a beta of 1.55. IDEXX Laboratories, Inc. has a fifty-two week low of $506.91 and a fifty-two week high of $769.98. The business has a 50-day moving average price of $562.26 and a 200 day moving average price of $621.32.
IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last released its earnings results on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, topping analysts’ consensus estimates of $3.41 by $0.06. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The company had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.12 billion. During the same quarter last year, the business posted $2.91 EPS. IDEXX Laboratories’s quarterly revenue was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. On average, sell-side analysts forecast that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current fiscal year.
About IDEXX Laboratories
IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.
IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.
Recommended Stories
- Five stocks we like better than IDEXX Laboratories
- Credo Technologies Accelerates AI—Its Stock Price Will Follow
- Qualcomm Goes All-In: The $10B Bet to Crush NVIDIA
- Jabil Just Gave Investors a Stronger Reason to Buy the Dip
- CarMax In Reverse? Why You Should Buy Now Before the Big Catalysts Emerge
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report).
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
